139 related articles for article (PubMed ID: 6777812)
41. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis.
Meltzer HY; Busch D
Psychiatry Res; 1983 Aug; 9(4):285-99. PubMed ID: 6580661
[TBL] [Abstract][Full Text] [Related]
42. Dopamine antagonism by thioridazine in schizophrenia.
Meltzer HY; Sachar EJ; Frantz AG
Biol Psychiatry; 1975 Feb; 10(1):53-7. PubMed ID: 1120175
[TBL] [Abstract][Full Text] [Related]
43. Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
Siris SG; Adan F; Lee A; Cooper TB; Mandeli J; Casey E
J Clin Psychiatry; 1988 Feb; 49(2):64-5. PubMed ID: 3338977
[TBL] [Abstract][Full Text] [Related]
44. Persistence of fluphenazine in plasma after decanoate withdrawal.
Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassay.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Hubbard JW; Midha KK
Ther Drug Monit; 1990 May; 12(3):268-76. PubMed ID: 2349611
[TBL] [Abstract][Full Text] [Related]
46. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
Marder SR; Hawes EM; Van Putten T; Hubbard JW; McKay G; Mintz J; May PR; Midha KK
Psychopharmacology (Berl); 1986; 88(4):480-3. PubMed ID: 3085136
[TBL] [Abstract][Full Text] [Related]
47. Determination of fluphenazine, related phenothiazine drugs and metabolites by combined high-performance liquid chromatography and radioimmunoassay.
Goldstein SA; Van Vunakis H
J Pharmacol Exp Ther; 1981 Apr; 217(1):36-43. PubMed ID: 6110775
[TBL] [Abstract][Full Text] [Related]
48. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
Schooler NR; Levine J
Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
[TBL] [Abstract][Full Text] [Related]
49. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
Turbott J; Villiger J; Hunter L
Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
[TBL] [Abstract][Full Text] [Related]
50. Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients.
Quitkin F; Rifkin A; Klein DF
Arch Gen Psychiatry; 1975 Oct; 32(10):1276-81. PubMed ID: 1101842
[TBL] [Abstract][Full Text] [Related]
51. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women.
Muck-Seler D; Pivac N; Mustapic M; Crncevic Z; Jakovljevic M; Sagud M
Psychiatry Res; 2004 Jul; 127(3):217-26. PubMed ID: 15296821
[TBL] [Abstract][Full Text] [Related]
52. Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms.
Naber D; Finkbeiner C; Fischer B; Zander KJ; Ackenheil M
Neuropsychobiology; 1980; 6(4):181-9. PubMed ID: 6104798
[TBL] [Abstract][Full Text] [Related]
53. A preliminary study of sex-related differences in prolactin responses to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients.
Nathan RS; Sachar EJ; Ostrow L; Asnis GM; Halbreich U; Halpern F; Renzi NL; Slotnick V
Psychopharmacology (Berl); 1983; 80(1):46-9. PubMed ID: 6408670
[TBL] [Abstract][Full Text] [Related]
54. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
55. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
56. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
MacCrimmon DJ; Saxena B; Foley P; Grof P
Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
[TBL] [Abstract][Full Text] [Related]
57. Fluphenazine activity and antipsychotic response.
Hitzemann RJ; Garver DL; Mavroidis M; Hirschowitz J; Zemlan FP
Psychopharmacology (Berl); 1986; 90(2):270-3. PubMed ID: 3097710
[TBL] [Abstract][Full Text] [Related]
58. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
McCreadie R; Mackie M; Morrison D; Kidd J
Br J Psychiatry; 1982 Mar; 140():280-6. PubMed ID: 7093596
[TBL] [Abstract][Full Text] [Related]
59. Neuroendocrine tests during treatment with neuroleptic drugs. II. The TRH test.
Braddock LE; Blake IM
Br J Psychiatry; 1981 Nov; 139():404-7. PubMed ID: 6120732
[TBL] [Abstract][Full Text] [Related]
60. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
Marder SR; Van Putten T; Aravagiri M; Hubbard JW; Hawes EM; McKay G; Midha KK
Psychopharmacol Bull; 1989; 25(3):479-82. PubMed ID: 2626520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
